Added to YB: 2026-02-06
Pitch date: 2026-02-04
NVO [neutral]
Novo Nordisk A/S
+1.7%
current return
Author Info
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 302.25
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
N/A
Re-Recontextualising Novo Nordisk - Not so cheap anymore
NVO (trimmed position 75%): 2026 guidance shows -5% to -13% sales/operating profit decline from Most Favoured Nation pricing pressures + intensifying GLP-1 competition. Despite strong Wegovy launch & litigation vs compounders, regulatory price cuts create uncertainty. 35-45B DKK FCF (2.2-2.8% yield) + 55B DKK capex. Long-term optimistic but near-term headwinds warrant caution.
Read full article (4 min)